No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3
Maxim Group Upgrades Nexalin Technology(NXL.US) to Buy Rating, Announces Target Price $5
Maxim Group Upgrades Nexalin Technology to Buy, Announces $5 Price Target
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup
10-K: FY2024 Annual Report
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV